GRPH Stock Price, Chart, Stats & News
Graphite Bio, Inc. (GRPH) is a dividend-paying stock with a current dividend yield of 0.00% as of Mar 21, 2024. It pays $0 per share over the trailing twelve months.
Dividend safety
Dividend coverage looks healthy — GRPH pays out about 0% of earnings.
GRPH chart
Fundamentals
Gross margin | 97.81% |
Operating margin | -477.46% |
Pretax margin | -427.62% |
Net margin | -430.25% |
Effective tax rate | -0.62% |
ROA | -26.85% |
ROE | -37.47% |
D/E | 0.00x |
Interest coverage ratio | – |
GRPH valuation
P/E | – |
P/S | 9.70x |
P/B | 0.32x |
P/CF | -5.61x |
P/FCF | -14.56x |
P/OCF | -5.61x |
PEG | 0.00x |
EV multiple | -2.36x |
About
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme.
Similar securities
Based on sector and market capitalization
